This country snapshot explores the challenges and opportunities for ensuring equitable access to lenacapavir in Colombia. Lenacapavir, a highly effective long-acting HIV prevention medicine administered only twice a year, has the potential to transform HIV prevention efforts. Yet at a time when HIV infections continue to rise in Colombia and across Latin America, access to this promising new tool remains uncertain. and is Barriers to access to lenacapavir include regulatory delays, high prices, patent protections and limited global supply.
The report examines Colombia’s current ability to access lenacapavir, including the drug’s regulatory status, affordability and availability. It analyses how patent monopolies and exclusion from generic licensing agreements could restrict access, while highlighting the legal and policy mechanisms available to improve affordability and expand supply. Drawing on Colombia’s recent experience using public-interest measures to increase access to essential medicines, the report also outlines practical actions for government, civil society and the pharmaceutical industry to help ensure that lenacapavir becomes available to everyone who could benefit from it.
